All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for a variety of hematologic malignancies; however, up to 50% of recipients develop acute graft-versus-host disease (aGvHD). aGvHD involving the gastrointestinal (GI) tract (GI-aGvHD) is difficult to treat, and in its most severe forms it carries a mortality rate of >95%. Any part of the GI tract may be affected, but the ileum is most commonly involved due to its high density of lymphoid follicles.
Surgical intervention in patients with GI-aGvHD is usually restricted to emergency presentations such as bowel perforation, GI hemorrhage, and intestinal necrosis. However, Justine Khodr et al., in Annals of Surgery,1 hypothesize that a proximal diverting enterostomy (DE), a procedure in which the bowel is brought out to the abdominal surface to form a stoma,2 could improve management of severe steroid-refractory GI-aGvHD in the distal excluded ileocolonic segment. The procedure diverts fecal matter away from the affected bowel, reducing bacterial translocation (the passage of bacteria through gut mucosa to normally sterile tissues3), which is implicated in GI-aGvHD pathophysiology. The results of their retrospective study are summarized in this article.
Figure 1. Identification of patients for inclusion*
allo-HSCT, allogeneic hematopoietic stem cell transplant; DE, diverting enterostomy; GI-aGvHD, acute graft-versus-host disease involving the gastrointestinal tract; MDT, multidisciplinary team.
*Adapted from Khodr, et al.1
Patient characteristics, presented in Table 1, did not differ significantly between the medical group and the DE group, except for cytomegalovirus status, which was significantly higher in the DE group (p = 0.003).
Table 1. Patient characteristics and transplantation modalities*
Characteristic, % (unless otherwise stated) |
Medical group |
DE group |
---|---|---|
Median age, years (IQR) |
54.5 (41.0–60.0) |
44.0 (38.0–49.0) |
Female |
36.8 |
53.8 |
Hematologic malignancy |
|
|
MM |
13.2 |
23.1 |
ALL |
2.6 |
30.8 |
HL |
0.0 |
7.7 |
NHL |
15.8 |
0.0 |
AML |
31.6 |
15.4 |
MDS |
0.0 |
7.7 |
CLL |
10.5 |
0.0 |
MPD |
15.8 |
15.4 |
CML |
10.5 |
0.0 |
Prophylactic digestive decontamination |
44.1 |
69.2 |
Positive recipient CMV serology |
31.6 |
69.2 |
Median plasma citrulline, mmmol/L (IQR)† |
26 (19–32) |
27 (17–33) |
ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; CMV, cytomegalovirus; DE, diverting enterostomy; HL, Hodgkin lymphoma; IQR, interquartile range, MDS, myelodysplastic syndrome; MM, multiple myeloma; MPD, myeloproliferative disorder; NHL, non-Hodgkin lymphoma. |
Characteristics of aGvHD, presented in Table 2, were comparable between both groups, with the exception of a significantly higher rate of proximal GI-aGvHD involving the jejunum in the medical treatment group (p < 0.0001).
Table 2. Characteristics of aGvHD*
Characteristic, % (unless otherwise stated) |
Medical group |
DE group |
---|---|---|
GI-aGvHD stage |
|
|
Stage 3 |
28.9 |
23.1 |
Stage 4 |
71.1 |
76.9 |
Proximal GI-aGvHD (involving jejunum)† |
74.9 |
7.7 |
Liver aGvHD stage |
|
|
No damage |
65.8 |
69.2 |
Stage 1 |
0.0 |
7.7 |
Stage 2 |
2.6 |
0.0 |
Stage 3 |
10.5 |
7.7 |
Stage 4 |
21.1 |
15.4 |
Skin aGvHD stage |
|
|
No damage |
34.2 |
46.2 |
Stage 1 |
18.4 |
7.7 |
Stage 2 |
18.4 |
30.8 |
Stage 3 |
18.4 |
7.7 |
Stage 4 |
10.5 |
7.7 |
No. of immunosuppressor lines |
|
|
n = 1 |
8.8 |
0.0 |
n = 2 |
38.2 |
61.5 |
n = 3 |
35.3 |
30.8 |
n = 4 |
17.6 |
0.0 |
n = 5 |
0.0 |
7.7 |
Missing data |
10.5 |
0.0 |
ICU stay during hospitalization |
65.6 |
76.9 |
Median delay from transplantation to aGvHD, days (IQR) |
30 (25–52) |
30 (27–40) |
Median plasma citrulline during aGvHD, mmmol/L (IQR) |
4 (3–6) |
3 (3–5) |
aGvHD, acute graft-versus-host disease; DE, diverting enterostomy; GI-aGvHD, aGvHD involving the gastrointestinal tract; ICU, intensive care unit; IQR, interquartile range. |
Table 3. Overall survival and causes of death*
Outcome, % |
Medical group |
DE group |
---|---|---|
1-year OS |
5 |
54 |
2-year OS |
2.5 |
31 |
Cause of death |
|
|
Relapse |
2.9 |
10 |
Hemorrhage (non-GI) |
10.5 |
0 |
Pneumonia |
22.9 |
20 |
Encephalitis |
2.8 |
0 |
Staphylococcal sepsis |
2.8 |
0 |
Liver failure |
5.7 |
20 |
Heart failure |
5.7 |
10 |
Respiratory failure |
5.7 |
20 |
Kidney failure |
5.7 |
10 |
GI complications |
45.7 |
30.8 |
Obstruction |
5.7 |
0 |
GI sepsis |
34.3 |
20 |
GI hemorrhage |
5.7 |
20 |
Overall infections |
57.9 |
30.8 |
DE, diverting enterostomy; GI, gastrointestinal; OS, overall survival. |
Severe postoperative complications occurred in three patients in the DE group, with one patient having volvulus of enterostomy requiring endoscopic treatment, the second developing cellulitis with enterocutaneous fistula leading to death 25 days post-operation, and the third experiencing GI perforation leading to death 35 days post-operation.
In the medical group, ten patients were considered for surgery but received medical treatment only: three were considered too frail for surgery, one improved with medical treatment, and six patients should have undergone DE but did not and all six died within the first year after GI-aGvHD onset.
DE significantly improved survival outcomes in patients with steroid-refractory GI-aGvHD compared to medical management alone and this supports previous findings from a smaller study.1 The effectiveness of DE is further validated given the significantly higher rate of cytomegalovirus infection in the DE group, a well-recognized cause of mortality in GI-aGvHD. However, notable limitations of this study include the small sample size, retrospective nature, and the fact that DE was preferentially performed in patients with distal GI-aGvHD, meaning the two groups were not entirely comparable. Given the poor survival rate in the medical group combined with the dramatic drop in citrulline levels in both groups, indicating deep intestinal failure and risk of bacterial translocation, Khodr and colleagues propose that DE should be considered in steroid-resistant GI-aGvHD regardless of GI-aGvHD location; research to assess this is ongoing.
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox